

Parameter	Retel <i>et al</i> (2010) <sup>133</sup>	Chen <i>et al</i> (2010) <sup>132</sup>
Country	Netherlands	USA
Perspective (costs)	Health care	Payer perspective
Comparators (NPI, Adjuvant! Online)	Adjuvant! Online vs. MammaPrint St Gallen vs. MammaPrint	Adjuvant! Online vs. MammaPrint
Starting age in the model	50 years	Unclear
Population	Early operable breast cancer, LN-, ER+, HER2+/-	≤60 years, ER+/-, LN-
Model structure (type, health states)	Markov model with four mutually exclusive health states (disease free, relapse, distant metastasis and death)	Markov model with three mutually exclusive health states (no recurrence, death from cancer, death from other causes)
Definition of relapse	Includes local, regional recurrence, secondary primary and contralateral breast cancer	Relapse included in terms of cost only (local, regional, contralateral, distant)
Time horizon	20 years	Lifetime (99% of patients dead)
Endocrine therapy regime	All patients are assumed to receive 2.5 years of tamoxifen followed by 2.5 years of aromatase inhibitor	Endocrine therapy only given to ER+ patients; tamoxifen for patients receiving endocrine therapy
Chemotherapy regime	80% receive 6 cycles of FEC; 10% receive 6 cycles of docetaxel, doxorubicin and cyclophosphamide (TAC); 10% receive AC + paclitaxel (4 + 12 cycles) in combination with trastuzumab	Cost based on the following chemotherapy regimens: alkylating agents (58%), anthracyclines (51%), taxanes (25%) and antimetabolites (18%)
Benefit of chemotherapy	HR for trastuzumab: 0.64 (95% CI 0.54 to 0.76)	Relative risk: 26% in ER+; 32% in ER-
Adverse events	CHF was included	Implicitly included in the cost of chemotherapy and QALYs
Quality of life	EQ-5D; utilities extracted from Lidgren <i>et al.</i> <sup>148</sup> No adjuvant systemic treatment (first year): 0.935 DFS (years 2–20): 0.935 Chemotherapy (year 1): 0.620 Endocrine therapy (years 1–5): 0.744 Trastuzumab (year 1): 0.620 CHF: 0.700 Relapse: 0.779 Distant recurrence: 0.685	Chemotherapy: 0.70 (6 months) Recurrence free: 0.98

Parameter	Retel <i>et al</i> (2010) <sup>133</sup>	Chen <i>et al</i> (2010) <sup>132</sup>
Costs and resources used	Cost expressed in 2005 euros; costs of health states extracted from Lidgren <i>et al.</i> <sup>144</sup> Chemotherapy: €8596 Endocrine therapy: €822 Trastuzumab: €36,298 CHF: €3453 Relapse (year 1): €12,181 Relapse (after): €2359 Distant metastasis (year 1): €14,303 Distant metastasis (after): €6813 MammaPrint: €2675	Cost expressed in 2007 US dollars Chemotherapy: \$35,964 Cost no recurrence (per year): \$5928 Recurrence: \$57,424 Terminal (cancer): \$76,557 Terminal (other): \$65,016 MammaPrint: \$4200 Endocrine therapy (per year): \$1383
Discounting	Costs: 4%; benefits: 1.5%	Costs: 3%; benefits: unclear
% of HER2+	10%	HER2+ excluded as assumed to receive trastuzumab anyway

Results for St Gallen or NCCN<sup>129</sup> are not presented in this table.